TherapeuticsMD, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(Unaudited - in thousands)

	Nine Months Ended September 30,
	2025	2024
Cash flows from operating activities:
Net Income (loss)	$50	$(2,433)
Less: income (loss) from discontinued operations, net of income taxes	91	(7)
Net loss from continuing operations	(41)	(2,426)
Adjustments to reconcile net loss to net cash provided by continuing operating activities:
Depreciation and amortization	287	409
Impairment of long-lived assets (Note 4)	—	1,261
Write-off of patents	119	—
Share-based compensation	24	240
Other	587	572
Changes in operating assets and liabilities:
Other assets	1,401	1,874
Prepaid and other current assets	(188)	17
Accounts payable	5	207
Accrued expenses and other current liabilities	509	(315)
Lease liabilities	(752)	(755)
Other non-current liabilities	128	69
Total adjustments	2,120	3,579
Net cash provided by continuing operating activities	2,079	1,153
Discontinued operations:
Net cash used in operating activities	(23)	(433)
Net cash used in discontinued operations	(23)	(433)
Net increase in cash	2,056	720
Cash and cash equivalents, beginning of period	5,059	4,327
Total cash and cash equivalents, end of period	$7,115	$5,047

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.